the sonoma bio logoa menu icon
 a back arrow
Sonoma Bio Home

Press Releases

Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases

June 8, 2022
Sonoma Biotherapeutics Appoints Heidi Hagen, MBA as Chief Technical Officer

November 16, 2021
Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary

September 16, 2021
Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases

August 4, 2021
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases

September 30, 2020
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases

February 6, 2020
HomeMissionCultureTeamSciencePipelineCareersNewsContact
HOMEMissionCultureTeamSciencePipelineCareersInvestorsNewsContact